The multiplicity of serotonin receptors: Uselessly diverse molecules or an embarrassment of riches?

被引:264
作者
Roth, BL
Lopez, E
Patel, S
Kroeze, WK
机构
[1] Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA
[2] Case Western Reserve Univ, Sch Med, Dept Psychiat, Cleveland, OH 44106 USA
[3] Case Western Reserve Univ, Sch Med, Dept Neurosci, Cleveland, OH 44106 USA
关键词
serotonin receptors; antidepressant; antipsychotic; clozapine; fluoxetine;
D O I
10.1177/107385840000600408
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
A large number of 5-HT receptors (>15) have been identified by molecular cloning technology over the past 10 years. This review briefly summarizes available information regarding the functional and therapeutic implications of serotonin receptor diversity for neurology and psychiatry. 5-HT receptors are divided into seven main families: 5-HT1, 5-HT2, 5-HT3, 5-HT4, 5-HT5, 5-HT6, and 5-HT7. Several families (e.g., 5-HT1 family) have many members (e.g., 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E, 5-HT1F), each of which is encoded by a distinct gene product. In addition to the genomic diversity of 5-HT receptors, splice variants and editing isoforms exist for many of the 5-HT receptors, making the family even more diverse. Evidence that is summarized in this review suggests that 5-HT receptors represent novel therapeutic targets for a number of neurologic and psychiatric diseases including migraine headaches, chronic pain conditions, schizophrenia, anxiety, depression, eating disorders, obsessive compulsive disorder, pervasive developmental disorders. and obesity-related conditions (Type II diabetes, hypertension, obesity syndromes). It is possible that subtype-selective serotonergic agents may revolutionize the treatment for a number of medical, psychiatric, and neurological disorders.
引用
收藏
页码:252 / 262
页数:11
相关论文
共 104 条
[71]   A COMPARISON OF THE BEHAVIORAL-EFFECTS OF ORAL VERSUS INTRAVENOUS MCPP ADMINISTRATION IN OCD PATIENTS AND THE EFFECT OF METERGOLINE PRIOR TO IV-MCPP [J].
PIGOTT, TA ;
HILL, JL ;
GRADY, TA ;
LHEUREUX, F ;
BERNSTEIN, S ;
RUBENSTEIN, CS ;
MURPHY, DL .
BIOLOGICAL PSYCHIATRY, 1993, 33 (01) :3-14
[72]  
Pineyro G, 1995, NEUROREPORT, V7, P353
[73]  
Rapport MM, 1997, PERSPECT BIOL MED, V40, P260
[74]   POTENCY OF ANTIPSYCHOTICS IN REVERSING THE EFFECTS OF A HALLUCINOGENIC DRUG ON LOCUS COERULEUS NEURONS CORRELATES WITH 5-HT2 BINDING-AFFINITY [J].
RASMUSSEN, K ;
AGHAJANIAN, GK .
NEUROPSYCHOPHARMACOLOGY, 1988, 1 (02) :101-107
[75]   FUNCTIONAL EXPRESSION OF HUMAN 5-HT1A-RECEPTORS AND DIFFERENTIAL COUPLING TO 2ND MESSENGERS IN CHO CELLS [J].
RAYMOND, JR ;
ALBERS, FJ ;
MIDDLETON, JP .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1992, 346 (02) :127-137
[76]  
RICKELS K, 1991, J CLIN PSYCHIAT, V52, P34
[77]   MULTIPLE MECHANISMS OF SEROTONERGIC SIGNAL TRANSDUCTION [J].
ROTH, BL ;
CHUANG, DM .
LIFE SCIENCES, 1987, 41 (09) :1051-1064
[78]   Activation is hallucinogenic and antagonism is therapeutic:: Role of 5-HT2A receptors in atypical antipsychotic drug actions [J].
Roth, BL ;
Willins, DL ;
Kristiansen, K ;
Kroeze, WK .
NEUROSCIENTIST, 1999, 5 (04) :254-262
[79]   D-4 DOPAMINE-RECEPTOR BINDING-AFFINITY DOES NOT DISTINGUISH BETWEEN TYPICAL AND ATYPICAL ANTIPSYCHOTIC-DRUGS [J].
ROTH, BL ;
TANDRA, S ;
BURGESS, LH ;
SIBLEY, DR ;
MELTZER, HY .
PSYCHOPHARMACOLOGY, 1995, 120 (03) :365-368
[80]  
ROTH BL, 1994, J PHARMACOL EXP THER, V268, P1403